BioVie Issues Letter to Shareholders
October 04, 2022 08:00 ET
|
BioVie, Inc.
Positive preliminary data from investigator-sponsored Phase 2 Alzheimer’s trial show high proportion of responders and level of cognitive improvements seen for NE3107 confirm NE3107’s status as one of...
BioVie to Participate in Cantor Fitzgerald’s Neurology & Psychiatry Conference
September 29, 2022 08:00 ET
|
BioVie, Inc.
RENO, Nev., Sept. 29, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced...
BioVie and Dr. Sheldon Jordan Jointly Announce Topline Results from an Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer’s Disease
September 07, 2022 06:00 ET
|
BioVie, Inc.
Vast majority of patients saw significant improvements in the Global Rating of Change (overall impression of patient’s daily abilities) with NE3107 treatment (p<0.0001 to p<0.05).NE3107 is...
BioVie Announces Patent Issuance Covering Ascites Treatment with BIV201
June 23, 2022 08:00 ET
|
BioVie, Inc.
CARSON CITY, Nev., June 23, 2022 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of advanced...
BioVie to Participate at the B. Riley Securities’ Neuro & Ophthalmology Conference
April 25, 2022 08:00 ET
|
BioVie, Inc.
CARSON CITY, Nev., April 25, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of...
BioVie Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®
March 10, 2022 08:00 ET
|
BioVie, Inc.
CARSON CITY, Nev., March 10, 2022 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and...
BioVie to Participate at the Oppenheimer Virtual Annual Healthcare Conference
March 09, 2022 16:05 ET
|
BioVie, Inc.
RENO, Nev., March 09, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced...
BioVie Announces Treatment of First Patient in Phase 2 Clinical Trial of NE3107 for the Treatment of Parkinson’s Disease
January 20, 2022 08:00 ET
|
BioVie, Inc.
RENO, Nev., Jan. 20, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced...
BioVie to Participate at the LifeSci Partners 11th Annual Corporate Access Event
December 28, 2021 08:00 ET
|
BioVie, Inc.
RENO, Nev., Dec. 28, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced...
BioVie Announces Partnership with the American Liver Foundation
December 09, 2021 08:00 ET
|
BioVie, Inc.
RENO, Nev., Dec. 09, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced...